FOLH1 and neoplasm: Our goal in this study is to solve these issues and improve the binding affinity and tumor uptake by replacing the pharmacophores with less lipophilic motifs, such as changing part of the PSMA-targeted pharmacophore from Ala(9-Anth) to 2-Nal and changing the quinoline motif in the FAP-targeted pharmacophore to a more hydrophilic pyridine.